Stocks/AKTX

Create a free account to see ACCE Scores

Sign up for free to unlock scores, score breakdowns, and stock analysis.

AKTX

↓ PDF (Pro)
Akari Therapeutics plc ADS
HealthcareBiotechnologyUnited StatesNASDAQ
$5.36
-4.63%today
MKT CAP
$6M
+17.3% · 1Y
Earnings History
-
+18.3%
+76.0%
-
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Analyst Targets
Current price
$5.36
Low
$26.78
Analyst Mean
$153.39
High
$280.00
2 analystsBuy
Full Financials
Trailing P/E-
Forward P/E-0.5x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ-
5y Revenue CAGR-
5y Earnings CAGR-
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership24.6%
Institutional Ownership9.9%
Short % of Float4.66%
Days to Cover0.5d
1 Week-2.3%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Top Holders
HolderType% HeldValueΔ SharesAs of
Armistice Capital, LLCinstitution5.95%$0.00B+100.00%2025-12-31
Cresset Asset Management, LLCinstitution1.80%$0.00B+0.00%2025-12-31
Warberg Asset Management LLCinstitution0.67%$0.00B+100.00%2025-12-31
Palo Alto Investors Lpinstitution0.32%$0.00B+0.00%2025-12-31
Jane Street Group, LLCinstitution0.16%$0.00B+100.00%2025-12-31
Xtx Topco Ltdinstitution0.11%$0.00B+100.00%2025-12-31
Cerity Partners LLCinstitution0.05%$0.00B+0.00%2025-12-31
Stonex Group Inc.institution0.05%$0.00B+100.00%2025-12-31
Skyview Financial Group LLCinstitution0.04%$0.00B+100.00%2025-12-31
Independent Advisor Allianceinstitution0.04%$0.00B+56.99%2025-12-31
RiverNorth Capital and Income Fundfund0.00%$0.00B+0.00%2025-12-31
RIVERNORTH OPPORTUNITIES FUND INC.-Rivernorth Opportunities Fund Incfund0.00%$0.00B+0.00%2025-12-31
TickerCapScoreP/EFwd P/EEV/EBITDAROEGrossD/EDiv
PTGX
Protagonist Therapeutics Inc. Common Stock
$6.6B5------0.00%
CELC
Celcuity Inc. Common Stock
$6.7B5------0.00%
ACLX
Arcellx Inc. Common Stock
$6.7B5-------
KYMR
Kymera Therapeutics Inc. Common Stock
$7.0B-----27.1%0%5.230.00%
TECH
Bio-Techne Corp Common Stock
$7.1B3672.724.4----63.00%
HALO
Halozyme Therapeutics Inc. Common Stock
$7.9B7325.56.6----0.00%
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Upgrade from $15/mo →
Growth73Value58Quality82Momentum61Total5
Score breakdown on Starter+
Upgrade →
Score History (90d)
Pro onlyUpgrade →
Updated 5/8/2026
Recent Alerts
No alerts yet for AKTX.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.